1. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133-41.
2. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984 Sep 15;98(3):271-82.
3. The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study. National Eye Institute. Clinical Trial: NCT00105027. Available at: /ct2/show/NCT00105027?term=SCORE&rank=4 (Accessed December 15, 2009).
4. The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology. 1995 Oct;102(10):1425-33.
5. Allergan. Ozurdex: How Ozurdex Works. Available at: /how-ozurdex- (Accessed December 15, 2009).
6. Haller JA, Dugel P, Weinberg DV, et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina. 2009 Jan;29(1):46-51.
7. Haller JA. Six-month randomized controlled clinical trial of an intravitreal dexamethasone implant in macular edema associated with retinal vein occlusion. Paper presented at the American Society of Retina Specialists Retina Congress 2009. New York: October 4, 2009.
8. Fialho SL, Behar-Cohen F, Silva-Cunha A. Dexamethasone-loaded poly (epsilon-caprolactone) intravitreal implants: a pilot study. Eur J Pharm Biopharm. 2008 Mar;68(3):637-46.
Plasma concentrations were obtained from 21 patients with macular edema due to branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), and 21 patients with diabetic macular edema (DME) prior to dosing and at 4 to 5 additional post-dose timepoints on Days 1, 7, 21, 30, 45, 60, and 90 following the administration of the first intravitreal implant containing mg dexamethasone. In RVO and DME patients, the majority of plasma dexamethasone concentrations were below the lower limit of quantitation (LLOQ = 50 pg/mL). Plasma dexamethasone concentrations from 12% of samples were above the LLOQ, ranging from 52 pg/mL to 102 pg/mL. Plasma dexamethasone concentration did not appear to be related to age, body weight, or sex of patients.